Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price traded down 15.3% on Monday . The company traded as low as $117.71 and last traded at $100.83. 3,370,915 shares changed hands during trading, an increase of 270% from the average session volume of 910,792 shares. The stock had previously closed at $119.10.
A number of equities analysts have weighed in on the company. Jefferies Group set a $156.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. Leerink Swann boosted their price target on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a research report on Thursday, January 25th. B. Riley lowered their price target on Alnylam Pharmaceuticals from $205.00 to $200.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Credit Suisse Group set a $151.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. Finally, BidaskClub raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, March 14th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $134.15.
The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02. The company has a market cap of $11,930.41, a PE ratio of -18.20 and a beta of 2.68.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.38) by ($0.10). The company had revenue of $37.90 million during the quarter, compared to the consensus estimate of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The company’s quarterly revenue was up 116.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.32) earnings per share. equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.88 EPS for the current fiscal year.
In related news, insider Akshay Vaishnaw sold 88,554 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $143.10, for a total value of $12,672,077.40. Following the completion of the sale, the insider now directly owns 55,856 shares in the company, valued at $7,992,993.60. The sale was disclosed in a filing with the SEC, which is available at this link. Also, President Barry E. Greene sold 38,460 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $143.10, for a total value of $5,503,626.00. Following the completion of the sale, the president now owns 97,544 shares of the company’s stock, valued at $13,958,546.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 235,365 shares of company stock valued at $33,239,418. 3.70% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the stock. Xact Kapitalforvaltning AB bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $1,819,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $4,384,000. Alkeon Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $635,000. Macquarie Group Ltd. boosted its stake in shares of Alnylam Pharmaceuticals by 214.5% in the fourth quarter. Macquarie Group Ltd. now owns 40,926 shares of the biopharmaceutical company’s stock valued at $5,200,000 after buying an additional 27,914 shares during the period. Finally, Vident Investment Advisory LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $262,000. Institutional investors and hedge funds own 92.28% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://theenterpriseleader.com/2018/04/02/alnylam-pharmaceuticals-alny-stock-price-down-15-3.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.